跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 25 条关于
“Kisulna”
全部
25
临床试验
0
药物
0
机构
0
资讯
25
去年
Donanemab Recommendations Offer Guidance for Alzheimer's Treatment
去年
Alzheimer's Disease Therapeutics: Donanemab Dosing, Anti-Tau Antibody E2814, and Combination Intranasal Insulin/Empagliflozin Show Promise
去年
Key Neurology Advances of 2024: From Novel Therapies to Trial Innovations
去年
FDA Clears Icobrain Aria: AI Tool for Enhanced ARIA Detection in Alzheimer's Treatments
去年
Novel CSF Biomarkers CHIT1 and DDAH1 May Predict ARIA Risk in Alzheimer's Patients Receiving Anti-Amyloid Therapies
去年
NICE Rejects Lilly's Kisunla for NHS Use Despite UK Regulatory Approval
2年前
FDA Approves Donanemab (Kisunla) for Early Alzheimer's Disease
去年
European Regulators Reject Eli Lilly's Alzheimer's Drug Kisunla Over Safety Concerns
去年
Modified Donanemab Dosing Reduces ARIA-E Risk in Early Alzheimer's Patients
去年
FDA Approves Donanemab (Kisunla) for Early Symptomatic Alzheimer's Disease
第 1 页,共 3 页
上一页
下一页